# Axsome Probability Of Bankruptcy

AXSM | Stock | ## USD 72.73 0.44 0.61% |

Axsome | Probability Of Bankruptcy |

## Axsome Probability Of Bankruptcy Analysis

Axsome Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Axsome Therapeutics Probability Of Bankruptcy | 39% |

Most of Axsome Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axsome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Axsome Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Axsome Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Axsome Therapeutics financial health.

Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 3.1 B | Return On Assets (0.42) | Return On Equity (1.60) |

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Axsome Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Axsome Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Axsome Therapeutics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Axsome Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Axsome Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Axsome Therapeutics' interrelated accounts and indicators.

**Click cells**to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Compare to competition |

Based on the latest financial disclosure, Axsome Therapeutics has a Probability Of Bankruptcy of 39.0%. This is 9.91% lower than that of the Pharmaceuticals sector and 28.88% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 2.08% higher than that of the company.

Chance Of Financial Distress

Less than 38

Axsome Therapeutics has

**less than 38 (%) percent**chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Axsome Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info## Axsome Therapeutics Main Bankruptcy Drivers

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Return on Average Assets | (78.47) | (121.59) | (57.94) | (50.6) | (95.21) | (102.73) | |

Total Debt | 9.93 M | 6.91 M | 19.93 M | 50.12 M | 49.71 M | 53.63 M | |

Total Liabilities | 18.84 M | 14.44 M | 41.83 M | 72.34 M | 72.15 M | 77.85 M | |

Current Liabilities | 12.18 M | 10.82 M | 24.49 M | 23.44 M | 23.07 M | 24.89 M | |

Total Assets | 35.56 M | 15.38 M | 220.55 M | 186.13 M | 87.79 M | 76.03 M | |

Current Assets | 35.3 M | 15.22 M | 220.38 M | 184.02 M | 86.52 M | 75.16 M | |

Net Cash Flow from Operations | (26.47 M) | (30.05 M) | (46.38 M) | (78.46 M) | (108.23 M) | (111.07 M) | |

Weighted Average Shares | 22.76 M | 26.88 M | 34.02 M | 37.21 M | 37.62 M | 40.59 M | |

Weighted Average Shares Diluted | 22.76 M | 26.88 M | 34.02 M | 37.21 M | 37.62 M | 40.59 M |

## Axsome Fundamentals

Return On Equity | (1.60) % | |||

Return On Asset | (0.42) % | |||

Operating Margin | (5.91) % | |||

Current Valuation | 2.33 B | |||

Shares Outstanding | 43.43 M | |||

Shares Owned by Insiders | 18.45 % | |||

Shares Owned by Institutions | 61.57 % | |||

Number of Shares Shorted | 6.79 M | |||

Price to Earning | (3.34) X | |||

Price to Book | 15.68 X | |||

Price to Sales | 121.45 X | |||

EBITDA | (124.71 B) | |||

Net Income | (130.4 B) | |||

Cash and Equivalents | 73.39 M | |||

Cash per Share | 1.82 X | |||

Total Debt | 49.09 M | |||

Debt to Equity | 6.20 % | |||

Current Ratio | 2.44 X | |||

Book Value Per Share | 3.62 X | |||

Cash Flow from Operations | (108.23 M) | |||

Short Ratio | 4.60 X | |||

Earnings Per Share | (3.72) X | |||

Target Price | 104.71 | |||

Number of Employees | 352 | |||

Beta | 1.75 | |||

Market Capitalization | 3.12 B | |||

Total Asset | 87.79 M | |||

Retained Earnings | (180.52 M) | |||

Working Capital | 28.02 M | |||

Current Asset | 34.76 M | |||

Current Liabilities | 6.74 M | |||

Z Score | -3.4 | |||

Net Asset | 87.79 M |

## About Axsome Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Axsome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.
## Axsome Therapeutics Investors Sentiment

The influence of Axsome Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Axsome. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.

Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Axsome Therapeutics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axsome Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axsome Therapeutics' short interest history, or implied volatility extrapolated from Axsome Therapeutics options trading.

## Pair Trading with Axsome Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.### Moving together with Axsome Therapeutics

+ | 0.62 | CGC | Canopy Growth Corp | Aggressive Push | PairCorr |

The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.

The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Please continue to Axsome Therapeutics Piotroski F Score and Axsome Therapeutics Altman Z Score analysis. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

## Complementary Tools for analysis

When running Axsome Therapeutics price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.

Price TransformationUse Price Transformation models to analyze depth of different equity instruments across global markets | Go | |

Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios | Go | |

Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | Go | |

CEO DirectoryScreen CEOs from public companies around the world | Go | |

Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format | Go |

Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 3.1 B | Return On Assets (0.42) | Return On Equity (1.60) |

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Axsome Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.